Abstract
Exercise-induced bronchospasm (EIB) involves airway obstruction with an onset shortly after exercising. It can occur in individuals without a diagnosis of asthma, but is most common in asthmatic patients (and in this scenario may be referred to a exercise-induced asthma, EIA), correlating with the patient's degree of airway hyperreactivity. While albuterol is the most commonly used rescue and prophylactic medication for EIB, the leukotriene antagonist, monetlukast, may be an appropriate choice for some patients. Clinical data have shown that once-daily treatment with montelukast (5 or 10 mg tablet) can offer protection against EIB within 3 days for some patients. Such an approach might be preferred for patients who have difficulty with inhaled medications and for children who cannot access their inhalers during the school day. Montelukast also may be an option to reduce side effects associated with albuterol for individuals who exercise regularly.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 23-30 |
| Number of pages | 8 |
| Journal | World Allergy Organization Journal |
| Volume | 3 |
| Issue number | 2 |
| DOIs | |
| State | Published - 2010 |
Fingerprint
Keywords
- Airway hyperreactivity
- Albuterol
- Asthma
- Bronchia hyperresponsiveness
- Exercise-induced bronchospasm
- Exerciseinduced asthma
- Montelukast
ASJC Scopus subject areas
- Immunology and Allergy
Cite this
Exercise-induced bronchospasm : Albuterol versus montelukast: Highlights of the asthma summit 2009: Beyond the guidelines. / Colice, Gene; Calhoun, William.
In: World Allergy Organization Journal, Vol. 3, No. 2, 2010, p. 23-30.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Exercise-induced bronchospasm
T2 - Albuterol versus montelukast: Highlights of the asthma summit 2009: Beyond the guidelines
AU - Colice, Gene
AU - Calhoun, William
PY - 2010
Y1 - 2010
N2 - Exercise-induced bronchospasm (EIB) involves airway obstruction with an onset shortly after exercising. It can occur in individuals without a diagnosis of asthma, but is most common in asthmatic patients (and in this scenario may be referred to a exercise-induced asthma, EIA), correlating with the patient's degree of airway hyperreactivity. While albuterol is the most commonly used rescue and prophylactic medication for EIB, the leukotriene antagonist, monetlukast, may be an appropriate choice for some patients. Clinical data have shown that once-daily treatment with montelukast (5 or 10 mg tablet) can offer protection against EIB within 3 days for some patients. Such an approach might be preferred for patients who have difficulty with inhaled medications and for children who cannot access their inhalers during the school day. Montelukast also may be an option to reduce side effects associated with albuterol for individuals who exercise regularly.
AB - Exercise-induced bronchospasm (EIB) involves airway obstruction with an onset shortly after exercising. It can occur in individuals without a diagnosis of asthma, but is most common in asthmatic patients (and in this scenario may be referred to a exercise-induced asthma, EIA), correlating with the patient's degree of airway hyperreactivity. While albuterol is the most commonly used rescue and prophylactic medication for EIB, the leukotriene antagonist, monetlukast, may be an appropriate choice for some patients. Clinical data have shown that once-daily treatment with montelukast (5 or 10 mg tablet) can offer protection against EIB within 3 days for some patients. Such an approach might be preferred for patients who have difficulty with inhaled medications and for children who cannot access their inhalers during the school day. Montelukast also may be an option to reduce side effects associated with albuterol for individuals who exercise regularly.
KW - Airway hyperreactivity
KW - Albuterol
KW - Asthma
KW - Bronchia hyperresponsiveness
KW - Exercise-induced bronchospasm
KW - Exerciseinduced asthma
KW - Montelukast
UR - http://www.scopus.com/inward/record.url?scp=77954904138&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954904138&partnerID=8YFLogxK
U2 - 10.1097/WOX.0b013e3181d25eac
DO - 10.1097/WOX.0b013e3181d25eac
M3 - Article
VL - 3
SP - 23
EP - 30
JO - World Allergy Organization Journal
JF - World Allergy Organization Journal
SN - 1939-4551
IS - 2
ER -